Please check your internet connection and try again.
# Meftal-Spas
## Overview
Meftal-Spas is a combination medication containing **Mefenamic acid** (a Non-Steroidal Anti-Inflammatory Drug/NSAID) and **Dicyclomine hydrochloride** (an antispasmodic/anticholinergic). It acts by inhibiting prostaglandin synthesis (via COX interference) and providing direct relaxation of smooth muscle in the gastrointestinal and genitourinary tracts.
## Primary Indications
* Management of spasmodic dysmenorrhea (primary).
* Symptomatic relief of abdominal cramps and gastrointestinal spasms.
* Treatment of mild-to-moderate pain associated with smooth muscle contraction.
## Adult Dosing
* **Standard dose:** 1 tablet (Mefenamic acid 250 mg / Dicyclomine 10 mg) taken 3 to 4 times daily.
* **Maximum dose:** Should not exceed 1000 mg of Mefenamic acid daily.
* **Duration:** Generally limited to 3–5 days due to the risks associated with NSAIDs.
## Pediatric Dosing
* **Safety/Efficacy:** Not established for general use in children under 12 years.
* **Note:** Use in pediatrics is off-label and generally avoided due to the risk of anticholinergic side effects (dicyclomine) and potential for Reye’s syndrome or renal toxicity (mefenamic acid). Consult local institutional guidelines before prescribing.
## Dose Adjustments
* **Renal Impairment:** Contraindicated in severe renal impairment (CrCl < 30 mL/min). Exercise caution in mild-to-moderate impairment.
* **Hepatic Impairment:** Use with caution; monitor for increased toxicity.
* **Elderly:** Use lowest effective dose for shortest duration; higher sensitivity to anticholinergic effects (dicyclomine risk of delirium/urinary retention).
## Contraindications
* Hypersensitivity to mefenamic acid, aspirin, or other NSAIDs.
* Active peptic ulceration or gastrointestinal bleeding.
* Severe renal or hepatic impairment.
* History of asthma or allergic-type reactions prompted by NSAIDs.
* **Dicyclomine-specific:** Obstructive uropathy, glaucoma, myasthenia gravis, paralytic ileus, or unstable cardiovascular status in acute hemorrhage.
## Adverse Effects
* **Common:** Dry mouth, dizziness, blurred vision, constipation, nausea, and drowsiness.
* **Serious:** Gastrointestinal bleeding/perforation, hypertension, acute renal failure, allergic reactions (anaphylaxis), and confusion (especially in the elderly due to dicyclomine).
## Key Drug Interactions
* **Anticoagulants (e.g., Warfarin):** Increases risk of bleeding.
* **Antihypertensives/Diuretics:** Mefenamic acid may decrease the efficacy of ACE inhibitors, ARBs, and diuretics.
* **Other NSAIDs/Steroids:** Significant increase in gastrointestinal ulceration risk.
* **Lithium/Methotrexate:** NSAIDs increase steady-state plasma levels, increasing toxicity risk.
* **CNS Depressants:** Dicyclomine may potentiate sedation from alcohol or antihistamines.
## Monitoring
* Monitor blood pressure periodically.
* Assess for gastrointestinal distress (nausea, dark/tarry stools).
* Renal function (BUN/Creatinine) for long-term or high-risk patients.
* Monitor for signs of anticholinergic toxicity (urinary retention, severe light sensitivity, confusion).
## Clinical Pearls
* **Avoid in pregnancy:** NSAIDs are generally contraindicated in the third trimester (premature closure of ductus arteriosus).
* **Take with food:** Always advise patients to take with a meal or milk to mitigate gastric irritation.
* **Avoid in high-risk tasks:** Dicyclomine can cause drowsiness; warn patients against driving or operating machinery until the effects are known.
* **Disclaimer:** Not recommended for long-term chronic pain management due to NSAID safety profile.
***
**Educational Disclaimer:** This information is for educational purposes only. Always verify specific dosing, safety precautions, and current prescribing information against the manufacturer's official labeling, local hospital protocols, or drug compendia (e.g., Lexicomp, BNF) before prescribing or administering medication.
